Product Code: VMR11218721
The global demand for Artificial Intelligence (AI) in Drug Discovery Market is presumed to reach the market size of nearly USD 27.25 BN by 2030 from USD 1.19 BN in 2022 with a CAGR of 47.9% under the study period of 2023 - 2030.
Artificial intelligence (AI) in Drug Discovery is a technology that employs machines to simulate human intelligence to solve challenging issues in the drug discovery process. The technology helps in discovering novel compounds and aids in the identification of therapeutic targets and the development of tailored medications. The system has numerous applications, including deriving insights into identifying drugs and lessening the severity of various chronic diseases. This market includes AI for drug discovery sales and related services.
MARKET DYNAMICS:
Some of the main drivers propelling the growth of AI in the drug delivery market include the rising usage of cloud-based applications and services and the impending patent expiration of blockbuster pharmaceuticals. Additional factors boosting demand are the growing need to control drug discovery costs and less time required for drug development. Further, the technology demand is also rising due to the discovery and development of novel pharmacological therapies and the expanding manufacturing capabilities of the life science industry. However, several problems are anticipated to impede the growth of this industry in the years to come, including a lack of skilled AI workers, hazy regulatory requirements for medical software, and a lack of data sets in this area. Nonetheless, the growing frequency of cross-industry partnerships will be a major driver influencing the market's development rate.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of artificial intelligence ( ai) in drug discovery. The growth and trends of Artificial Intelligence ( AI) in Drug Discovery Industry provide a holistic approach to this study.
MARKET SEGMENTATION:
This section of the artificial intelligence ( ai) in drug discovery market report provides detailed data on the segments by analyzing them at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Offering
By Technology
- Machine Learning
- Deep Learning
- Supervised Learning
- Reinforcement Learning
- Unsupervised Learning
- Other Machine Learning Technologies
- Other Technologies
By Application
- Immuno-Oncology
- Neurodegenerative Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Other Applications
By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Research Centers And Academic & Government Institutes
REGIONAL ANALYSIS:
This section covers the regional outlook, which accentuates current and future demand for the Artificial Intelligence ( AI) in Drug Discovery market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the artificial intelligence ( ai) in drug discovery market include Microsoft Corporation (US), Exscientia (UK), NVIDIA Corporation (US), Schrodinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), Google (US), Insilico Medicine (US), BERG LLC (US), Cloud Pharmaceuticals (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), XtalPi (US), Verge Genomics (US), Owkin, Inc. (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Offering
- 3.7.2 Market Attractiveness Analysis By Technology
- 3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET ANALYSIS BY OFFERING
- 5.1 Overview by Offering
- 5.2 Historical and Forecast Data
- 5.3 Analysis by Offering
- 5.4 Software Historic and Forecast Sales by Regions
- 5.5 Services Historic and Forecast Sales by Regions
6 . GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET ANALYSIS BY TECHNOLOGY
- 6.1 Overview by Technology
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Technology
- 6.4 Machine Learning Historic and Forecast Sales by Regions
- 6.5 Deep Learning Historic and Forecast Sales by Regions
- 6.6 Supervised Learning Historic and Forecast Sales by Regions
- 6.7 Reinforcement Learning Historic and Forecast Sales by Regions
- 6.8 Unsupervised Learning Historic and Forecast Sales by Regions
- 6.9 Other Machine Learning Technologies Historic and Forecast Sales by Regions
- 6.10. Other Technologies Historic and Forecast Sales by Regions
7 . GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET ANALYSIS BY GEOGRAPHY
- 7.1. Regional Outlook
- 7.2. Introduction
- 7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
- 7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
- 7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. Rest Of Asia Pacific Sales Analysis
- 7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
- 7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis
8 . COMPETITIVE LANDSCAPE OF THE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY COMPANIES
- 8.1. Artificial Intelligence (Ai) In Drug Discovery Market Competition
- 8.2. Partnership/Collaboration/Agreement
- 8.3. Merger And Acquisitions
- 8.4. New Product Launch
- 8.5. Other Developments
9 . COMPANY PROFILES OF ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY INDUSTRY
- 9.1. Top Companies Market Share Analysis
- 9.2. Market Concentration Rate
- 9.3. Microsoft Corporation (US)
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
- 9.4. Exscientia (UK)
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
- 9.5. NVIDIA Corporation (US)
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
- 9.6. Schrodinger (US)
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
- 9.7. Atomwise Inc. (US)
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
- 9.8. BenevolentAI (UK)
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
- 9.9. NuMedii (US)
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
- 9.10. Google (US)
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
- 9.11. Insilico Medicine (US)
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
- 9.12. BERG LLC (US)
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
- 9.13. Cloud Pharmaceuticals (US)
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments
- 9.14. Cyclica (Canada)
- 9.14.1. Company Overview
- 9.14.2. Company Revenue
- 9.14.3. Products
- 9.14.4. Recent Developments
- 9.15. Deep Genomics (Canada)
- 9.15.1. Company Overview
- 9.15.2. Company Revenue
- 9.15.3. Products
- 9.15.4. Recent Developments
- 9.16. IBM (US)
- 9.16.1. Company Overview
- 9.16.2. Company Revenue
- 9.16.3. Products
- 9.16.4. Recent Developments
- 9.17. BIOAGE (US)
- 9.17.1. Company Overview
- 9.17.2. Company Revenue
- 9.17.3. Products
- 9.17.4. Recent Developments
- 9.18. Valo Health (US)
- 9.18.1. Company Overview
- 9.18.2. Company Revenue
- 9.18.3. Products
- 9.18.4. Recent Developments
- 9.19. Envisagenics (US)
- 9.19.1. Company Overview
- 9.19.2. Company Revenue
- 9.19.3. Products
- 9.19.4. Recent Developments
- 9.20. twoXAR (US)
- 9.20.1. Company Overview
- 9.20.2. Company Revenue
- 9.20.3. Products
- 9.20.4. Recent Developments
- 9.21. XtalPi (US)
- 9.21.1. Company Overview
- 9.21.2. Company Revenue
- 9.21.3. Products
- 9.21.4. Recent Developments
- 9.22. Verge Genomics (US)
- 9.22.1. Company Overview
- 9.22.2. Company Revenue
- 9.22.3. Products
- 9.22.4. Recent Developments
- 9.23. Owkin Inc. (US)
- 9.23.1. Company Overview
- 9.23.2. Company Revenue
- 9.23.3. Products
- 9.23.4. Recent Developments
- 9.24. Biovista (US)
- 9.24.1. Company Overview
- 9.24.2. Company Revenue
- 9.24.3. Products
- 9.24.4. Recent Developments
- 9.25. Evaxion Biotech (Denmark)
- 9.25.1. Company Overview
- 9.25.2. Company Revenue
- 9.25.3. Products
- 9.25.4. Recent Developments
- 9.26. Iktos (France)
- 9.26.1. Company Overview
- 9.26.2. Company Revenue
- 9.26.3. Products
- 9.26.4. Recent Developments
- 9.27. Standigm (South Korea)
- 9.27.1. Company Overview
- 9.27.2. Company Revenue
- 9.27.3. Products
- 9.27.4. Recent Developments
- 9.28. BenchSci (Canada)
- 9.28.1. Company Overview
- 9.28.2. Company Revenue
- 9.28.3. Products
- 9.28.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies